As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health ...

Experts from NASA are keeping a close eye on UK ... the GLP-1 used in AZ's diabetes drug Bydureon. NASA’s chief health and medical officer Dr James Polk said: “Although our mechanism for ...

GLP1RA mimics the GLP-1 hormone in the body that helps control ... Strawbridge, Ph.D., of the University of Glasgow, in the UK. More information: Madeleine M. E. Hayman et al, Association of ...

Over a median of 3.68 years, adults with type 2 diabetes who added a GLP-1 agent to their treatment ... were likely driven by two main mechanisms of action -- the first being a reduction in ...

prompting companies to not only develop drugs with a similar mechanism of action (MOA), but also to explore and investigate novel targets. While Wegovy was not the first GLP-1 receptor agonist ...

These are likely mechanisms by which GLP-1 may impact neuropsychiatric conditions.” — Ziyad Al-Aly, MD “I think there is clearly (an) added benefit for several conditions. For example ...